The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

Annales Pharmaceutiques Francaises, an esteemed journal published by MASSON EDITEUR, serves as a pivotal platform in the field of Pharmaceutical Science and Pharmacology. Established in 1945 and continuing through 2024, this journal showcases significant contributions to the advancement of pharmaceutical sciences, bridging the gap between research, development, and practical applications. Although it currently does not offer open access, its established reputation and Q3 ranking in both Pharmaceutical Science and Pharmacology highlight its role in disseminating impactful studies. With an ISSN of 0003-4509, the journal is indexed in Scopus, boasting a respectable percentile ranking for both domains, and remains a vital resource for researchers, professionals, and students dedicated to exploring the latest advancements in the pharmaceutical field. Based in France, at 21 Street Camille Desmoulins, Issy, 92789 Moulinais Cedex 9, it aims to foster a deeper understanding of pharmacological innovations and therapeutic agents among its diverse readership.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

The Journal of Pharmacy and Bioallied Sciences is a premier open access publication that has been contributing to the fields of Pharmacy, Bioengineering, and Biochemistry since its establishment in India, under the esteemed Wolters Kluwer Medknow Publications. With the ISSN 0976-4879 and E-ISSN 0975-7406, this journal provides a platform for high-quality research articles, reviews, and clinical studies aimed at advancing knowledge and practice in the pharmaceutical and allied sciences. As a reflection of its academic stature, the journal holds a respectable categorization within the third and fourth quartiles in pertinent fields according to the latest metrics, with rankings that place it among prominent emerging research in pharmacology and biochemistry. Researchers and professionals are encouraged to access a wealth of knowledge freely, as the journal has been open access since 2010. The journal not only aims to foster innovative research but also strives to bridge the gap between pharmaceutical sciences and real-world applications, making it an essential resource for students, academics, and industry experts alike.

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

Pharmacy is a premier open-access journal published by MDPI, dedicated to advancing research in the dynamic field of pharmaceutical sciences. Since its inception in 2013, this journal has become a vital platform for disseminating novel findings, reviews, and insights related to drug development, pharmacokinetics, pharmaceutical technology, and clinical applications. With an E-ISSN of 2226-4787, Pharmacy prioritizes accessibility and visibility, allowing researchers, professionals, and students from around the globe to engage with cutting-edge research without barriers. The journal plays a crucial role in shaping pharmaceutical education and practice, fostering innovative ideas and collaborative approaches aimed at improving health outcomes. As part of the MDPI family, Pharmacy is committed to maintaining high-quality standards, ensuring that all published articles undergo rigorous peer review.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

Integrated Pharmacy Research and Practice is a peer-reviewed, open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of pharmacy through innovative research and practice. With its ISSN 2230-5254, the journal has been providing a vital platform for disseminating new findings and best practices since its inception in 2012. Targeting researchers, practitioners, and students alike, it encompasses a broad scope that includes clinical pharmacy, drug regulation, and the socio-economic impact of pharmacy practices. Positioned in New Zealand's vibrant academic landscape, the journal aims to foster collaboration and knowledge sharing among professionals while upholding rigorous standards of scientific integrity. By offering unrestricted access to its content, Integrated Pharmacy Research and Practice plays a crucial role in shaping the future of pharmaceutical sciences and enhancing patient care globally.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.